SOUTH SAN FRANCISCO, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations.
In this role, Kreger leads global manufacturing, supply chain, demand planning, and distribution for Fluidigm. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, Kreger will be responsible for driving long-term strategic changes and process improvements to boost efficiency as well as overall operational effectiveness.
“Brad’s unique skills and background will drive us to the next level of success. He has a proven track record of managing cost, driving productivity, and delivering on rapid growth without compromising the customer experience,” said Linthwaite. “He brings meaningful leadership experience in life science tools across proteomics and genomics and across instruments and reagents, in both regulated and non-regulated business environments.”
Prior to joining Fluidigm, Kreger was Senior Director, Manufacturing Operations, Clinical Next-Generation Sequencing Division, at Thermo Fisher Scientific. Previously, Kreger spent two decades at Affymetrix, most recently as VP, Reagent Manufacturing & Global Process Engineering. In that role, he served as site leader for the primary reagent manufacturing site and oversaw all reagent manufacturing and global engineering activities.
“Research powered by Fluidigm technology is enabling discoveries in human health that have the potential to improve lives, and I am delighted to have the opportunity to support that mission,” said Kreger.
Kreger holds an MBA from Western Governors University and a BS degree in biotechnology and business from Charter Oak State College.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, and Fluidigm system and consumable product names are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and development of additional products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships and international regulated markets; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Corporate Communications
650 243 6621